Tags

Type your tag names separated by a space and hit enter

Palliative treatment of cancer anorexia with oral suspension of megestrol acetate.
Neoplasma. 2003; 50(3):227-33.N

Abstract

Megestrol acetate (MA) is a progestational agent, currently known as one of the most effective appetite stimulants in patients suffering from cancer anorexia/cachexia syndrome. Oral suspension of this drug may be particularly useful in patients with far advanced disease, where taking larger amount of pills may lead to the decrease of patient compliance. The influence of oral MA suspension on quality of life and nutritional status was evaluated in 22 patients with far advanced cancer suffering from anorexia and more than 5 per cent weight loss, all beyond the scope of anticancer treatment. Most patients had lung or gastrointestinal cancer. QLQ-C30 questionnaire, visual analogue scale (VAS) for appetite, anthropometry, maximal handgrip strength and laboratory data were obtained before treatment and then after 2, 4, and 8 weeks of therapy. Despite of a known high mortality in this prognostically unfavorable group of patients (36% within two months in this study), overall quality of life after the daily dose of 480-840 mg of MA was improved in 63, 56, and 55% of patients remaining on therapy after 2, 4, and 8 weeks, respectively. Appetite was the most successfully influenced parameter with an improvement in VAS in 95% of cases after 2 weeks of therapy (p=0.0001). The drug was well tolerated by the great majority of patients. Oral suspension of megestrol acetate maybean effective palliative treatment for many patients with far advanced cancer suffering from anorexia/cachexia syndrome.

Authors+Show Affiliations

Department of Internal Medicine-Hematooncology, Masaryk University Hospital, 62500 Brno, Czech Republic. mtomiska@fnbrno.czNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12937858

Citation

Tomíska, M, et al. "Palliative Treatment of Cancer Anorexia With Oral Suspension of Megestrol Acetate." Neoplasma, vol. 50, no. 3, 2003, pp. 227-33.
Tomíska M, Tomisková M, Salajka F, et al. Palliative treatment of cancer anorexia with oral suspension of megestrol acetate. Neoplasma. 2003;50(3):227-33.
Tomíska, M., Tomisková, M., Salajka, F., Adam, Z., & Vorlícek, J. (2003). Palliative treatment of cancer anorexia with oral suspension of megestrol acetate. Neoplasma, 50(3), 227-33.
Tomíska M, et al. Palliative Treatment of Cancer Anorexia With Oral Suspension of Megestrol Acetate. Neoplasma. 2003;50(3):227-33. PubMed PMID: 12937858.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Palliative treatment of cancer anorexia with oral suspension of megestrol acetate. AU - Tomíska,M, AU - Tomisková,M, AU - Salajka,F, AU - Adam,Z, AU - Vorlícek,J, PY - 2003/8/26/pubmed PY - 2003/9/13/medline PY - 2003/8/26/entrez SP - 227 EP - 33 JF - Neoplasma JO - Neoplasma VL - 50 IS - 3 N2 - Megestrol acetate (MA) is a progestational agent, currently known as one of the most effective appetite stimulants in patients suffering from cancer anorexia/cachexia syndrome. Oral suspension of this drug may be particularly useful in patients with far advanced disease, where taking larger amount of pills may lead to the decrease of patient compliance. The influence of oral MA suspension on quality of life and nutritional status was evaluated in 22 patients with far advanced cancer suffering from anorexia and more than 5 per cent weight loss, all beyond the scope of anticancer treatment. Most patients had lung or gastrointestinal cancer. QLQ-C30 questionnaire, visual analogue scale (VAS) for appetite, anthropometry, maximal handgrip strength and laboratory data were obtained before treatment and then after 2, 4, and 8 weeks of therapy. Despite of a known high mortality in this prognostically unfavorable group of patients (36% within two months in this study), overall quality of life after the daily dose of 480-840 mg of MA was improved in 63, 56, and 55% of patients remaining on therapy after 2, 4, and 8 weeks, respectively. Appetite was the most successfully influenced parameter with an improvement in VAS in 95% of cases after 2 weeks of therapy (p=0.0001). The drug was well tolerated by the great majority of patients. Oral suspension of megestrol acetate maybean effective palliative treatment for many patients with far advanced cancer suffering from anorexia/cachexia syndrome. SN - 0028-2685 UR - https://www.unboundmedicine.com/medline/citation/12937858/Palliative_treatment_of_cancer_anorexia_with_oral_suspension_of_megestrol_acetate_ L2 - http://www.aepress.sk/_downloads/dl.php?from=pubmed&journal=NEO&file=2003_03_227.pdf DB - PRIME DP - Unbound Medicine ER -